Nippon Kayaku said on September 30 that it has filed its biosimilar versions of the anti-TNF-α monoclonal antibody Humira (adalimumab) for an additional indication of non-radiographic axial spondyloarthritis (nr-axSpA) in Japan.Subject to the filing is Adalimumab BS Subcutaneous Injection 40…
To read the full story
Related Article
- Nippon Kayaku’s Humira Biosimilar Adds nr-axSpA Use
March 21, 2025
- Humira Filed for nr-axSpA in Japan Based on Public Knowledge: AbbVie
September 2, 2024
BUSINESS
- Lunsumio Combo Hits PIII Goal in Follicular Lymphoma: Roche
September 18, 2026
- Padcev-Keytruda Gets CHMP Nod for Expanded MIBC Use
September 18, 2026
- SanBio Eyes October Start for Akuugo Treatment
September 18, 2026
- Toho Unit to Launch Pharma-Wholesaler Payment Service
September 18, 2026
- Astellas Names Marino General Counsel, Compliance Chief
September 18, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…





